| | | | | | | | Pharma Manufacturing editors Karen Langhauser and Andrea Corona comment on the notable happenings in the pharma industry from the week of September 4 |
|
|
|
| |
| | |
|
|
| | | | | With the ink still wet on its psychedelics buy, Otsuka will put up a potential $1.5 billion to develop intravitreally-delivered AAVs for ocular diseases. |
|
|
| Verge will receive $42 million upfront in a neurodegenerative and neuromuscular deal that could reach $840 million. |
|
|
|
| |
| | |
|
|
| | | | Sponsored | Aseptic filling & freezing of single-use bags are often performed manually and uncontrolled, leading to inefficiencies and increased product loss. Only modular technologies facilitate flexible manufacturing processes of mRNA, pDNA and viral vectors. |
|
|
|
| |
| | |
|
|
| | |
|
| | |
|
